FOSAMPRENAVIR CALCIUM

Search structure
Trade Names:
Synonyms:
Status: Approved (2003)
Entry Type: Small molecule
Molecule Category: Salt Prodrug
UNII: ID1GU2627N
Parent Compound: FOSAMPRENAVIR

Structure
InChI Key PMDQGYMGQKTCSX-HQROKSDRSA-L
Smile CC(C)CN(C[C@@H](OP(=O)([O-])[O-])[C@H](Cc1ccccc1)NC(=O)O[C@H]1CCOC1)S(=O)(=O)c1ccc(N)cc1.[Ca+2]
InChI
InChI=1S/C25H36N3O9PS.Ca/c1-18(2)15-28(39(33,34)22-10-8-20(26)9-11-22)16-24(37-38(30,31)32)23(14-19-6-4-3-5-7-19)27-25(29)36-21-12-13-35-17-21;/h3-11,18,21,23-24H,12-17,26H2,1-2H3,(H,27,29)(H2,30,31,32);/q;+2/p-2/t21-,23-,24+;/m0./s1

Physicochemical Descriptors

Property Name Value
Molecular Formula C25H34CaN3O9PS
Molecular Weight 623.68
AlogP 2.52
Hydrogen Bond Acceptor 8.0
Hydrogen Bond Donor 4.0
Number of Rotational Bond 13.0
Polar Surface Area 177.72
Molecular species ACID
Aromatic Rings 2.0
Heavy Atoms 39.0

Pharmacology

Action Mechanism of Action Reference
INHIBITOR Human immunodeficiency virus type 1 protease inhibitor FDA

Indications

Mesh Heading Maximum Phase Mesh ID Reference
Laryngopharyngeal Reflux 3 D057045 ClinicalTrials

Related Entries

Scaffolds

Parent

Adverse Reactions

SOC By Demographic Distribution
System Organ Classification (SOC)
Relative Frequency (%)
Gastrointestinal disorders
8.92
Metabolism and nutrition disorders
7.61
Injury, poisoning and procedural complications
7.22
Infections and infestations
7.09
Skin and subcutaneous tissue disorders
7.09
General disorders and administration site conditions
6.96
Investigations
6.56
Nervous system disorders
6.04
Hepatobiliary disorders
5.51
Immune system disorders
5.25
Musculoskeletal and connective tissue disorders
4.59
Pregnancy, puerperium and perinatal conditions
4.07
Blood and lymphatic system disorders
3.67
Vascular disorders
3.41
Renal and urinary disorders
2.76
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
2.36
Psychiatric disorders
2.36
Respiratory, thoracic and mediastinal disorders
2.36

Cross References

Resources Reference
ChEMBL CHEMBL1200734
EPA CompTox DTXSID0046777
FDA SRS ID1GU2627N
PubChem 131535
SureChEMBL SCHEMBL1649283
CONTENTS